Anaesthetic drugs & techniques
Effect of postoperative esketamine on depression after pancreatoduodenectomy: a randomized controlled trial
Authors' conclusion
The postoperative administration of esketamine may reduce the need for analgesics among patients undergoing PD, alleviate peripheral inflammation, and potentially improve postoperative depressive symptoms.
Study context
- Population
- Patients scheduled for pancreaticoduodenectomy (PD)
- Participants
- 80 patients
- Comparison
- Esketamine vs Control
- Primary endpoint
- Incidence of depression
- Follow-up
- Third postoperative day
Primary result
As reported in the abstract
- Did not differ significantly between the two groups (47.1% vs. 42.9%, group order as printed)
- Esketamine vs Control: P = 0.726
Secondary outcomes
| Outcome | Esketamine | Control | P value |
|---|---|---|---|
| Change in HAMD-17 score, baseline to fifth postoperative day | P = 0.029 | ||
| Number of PCIA button presses | 6.54 ± 4.39 | 9.32 ± 6.48 | P = 0.040 |
| Opioid usage | 100.9 ± 25.72 | 114.9 ± 23.32 | P = 0.021 |
| Plasma IL-6 · first postoperative day | P < 0.05 | ||
| Plasma TNF-α · fifth postoperative day | P < 0.05 |
Change in HAMD-17 score, baseline to fifth postoperative day
- Significantly lower in the esketamine group
Plasma IL-6 · first postoperative day
- Esketamine decreased plasma IL-6
Plasma TNF-α · fifth postoperative day
- Esketamine decreased plasma TNF-α
Original publication
Effect of postoperative esketamine on depression after pancreatoduodenectomy: a randomized controlled trial. Perioper Med (Lond). Published 12 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →